Comparative Pharmacology
Head-to-head clinical analysis: BRISTAMYCIN versus E MYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRISTAMYCIN versus E MYCIN.
BRISTAMYCIN vs E-MYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BRISTAMYCIN is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and activating autolytic enzymes.
Erythromycin binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by blocking the translocation of peptidyl-tRNA. It may also act as a motilin receptor agonist, enhancing gastrointestinal motility.
500 mg intravenously every 6 hours. Infuse over 60 minutes.
250-500 mg orally every 6 hours or 500 mg every 12 hours; maximum 4 g/day.
None Documented
None Documented
Terminal elimination half-life: 6–8 hours (prolonged to 20–40 hours in severe renal impairment; dose adjustment required for CrCl <30 mL/min).
1.5-2 hours in adults with normal renal function; prolonged to 4-6 hours in severe hepatic impairment; no significant change in renal impairment due to minimal renal clearance.
Renal: 80–90% unchanged via glomerular filtration and tubular secretion; biliary/fecal: <5% as unchanged drug and metabolites.
Primarily hepatic metabolism and biliary excretion with significant enterohepatic circulation; approximately 2-15% excreted unchanged in urine; 10-40% excreted in feces via bile; less than 1% eliminated as unchanged drug in feces from unabsorbed drug.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic